A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy

British Journal of Cancer

Volumn 84, Issue SUPPL. 1, 2001, Pages 17-23

  Glaspy, J ^a   Jadeja, J Singh ^b   Justice, G ^c   Kessler, J ^d   Richards, D ^e   Schwartzberg, L ^f   Rigas, J ^g   Kuter, D ^h   Harmon, D ^h   Prow, D ⁱ   Demetri, G ^j   Gordon, D ^k   Arseneau, J ^l   Saven, A ^m   Hynes, H ⁿ   Boccia, R ^o   O'Byrne, J ^p   Colowick, A B ^p  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Hematology Oncology Associates of Jacksonville   (United States)

^c Pacific Coast Hematology/Oncology Medical Group   (United States)

^d Virginia Oncology Associates   (United States)

^e Tyler Cancer Center   (United States)

^f WEST CLINIC   (United States)

^g DARTMOUTH MEDICAL SCHOOL   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ Texas Cancer Care   (United States)

^j HARVARD MEDICAL SCHOOL   (United States)

^k San Antonio Tumor and Blood Clinic   (United States)

^l Albany Regional Cancer Center   (United States)

^m SCRIPPS CLINIC   (United States)

ⁿ Cancer Center of Kansas   (United States)

^o Associates in Oncol and Hematology   (United States)

^p AMGEN INC   (United States)

more..

Author keywords

Anaemia; Cancer; Chemotherapy; Darbepoetin alfa; Solid tumours; Transfusion

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; DARBEPOIETIN ALFA; ERYTHROPOIETIN; HEMOGLOBIN; HUMAN SERUM ALBUMIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; SIALIC ACID; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; SOLID TUMOR;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD TRANSFUSION; COHORT STUDIES; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; ERYTHROPOIETIN; FEMALE; HALF-LIFE; HEMOGLOBINS; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; N-ACETYLNEURAMINIC ACID; NEOPLASMS; RECOMBINANT PROTEINS; SAFETY; TREATMENT OUTCOME;

EID: 0035021354     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1754     Document Type: Article

References (22)

1. Abels RI (1992) Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer. Semin Oncol 19; 29-35
2. Argiles JM and Lopez-Soriano FJ (1999) The role of cytokines in cancer cachexia. Med Res Rev 19: 223-248
3. Cascinu S, Fedeli A, Del Ferro E, Luzi Fedeli S and Catalano G (1994) Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized double-blind trial with placebo. J Clin Oncol 12: 1058-1062
4. Cella D (1998) Factors influencing quality of life in cancer patients: anemia and fatigue, Semin Oncol 25: 43-46
5. Cleeland CS, Demetri GD and Glaspy J (1999) Identifying hemoglobin levels for optimal quality of life: results of an incremental analysis. Proc Am Soc Clin Oncol 18: 574a (abstract 2215)
6. Curt GA (2000) Impact of fatigue on quality of lift in oncology patients, Semin Hematol 37: 14-17
7. Demetri GD, Kris M, Wade J, Degos L and Cella D (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16; 3412-3425
8. Egrie JC, Dwyer E, Lykos M, Hitz A and Browne JK (1997) Novel erythropoiesis stimulating protein (NESP) has a longer serum half-life and greater in vivo biological activity than recombinant human erythropoietin (rHuEPO). Blood 90: 56a-57a (abstract 243)
9. Gabrilove JL, Einhom LH. Livingston RB, Winer E and Cleeland CS (1999) Once-weekly dosing of Epoetin alfa is similar to three times weekly dosing in increasing hemoglobin and quality of life. Proc Am Soc Clin Oncol 18: 574a (abstract 2216)
10. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S and Vadhan-Raj S (1997) Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyleoid malignancies during cancer chemotherapy in community oncology practice, Procrit Study Group. J Clin Oncol 15: 1218-1234
11. 1/2) in oncology patients (pts). Proc Am Soc Clin Oncol 19: 54a (abstract 210)
12. Goodnough LT. Skikne B and Brugnara C (2000) Erythropoietin. iron. and erythropoiesis, Blood 96: 823-833
13. Heatherington AC, Schuller J and Mercer AJ (2001) Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report. Br J Cancer 84 (Supp 1): 11-16
14. Jelkmann W (1998) Proinflammatory cytokines lowering erythropoeitin production. J Interferon Cytokine Res 18: 555-559
15. Kotasek D, The ARANESP 980291 Study Group. Berg R, Poulsen E and Colowick A (2000) Randomized, double-blind, placebo controlled phase I/II dose finding study of ARANESP™ administered once every three weeks in solid tumor patients. Blood 96: 294a-295a (abstract 1268)
16. Koury MJ and Bondurant MC (1990) Control of red cell production: the roles of programmed cell death (apoptosis) and erythropoeitin. Transfusion 30: 673-674
17. Littlewood TJ. Rapoport B and Bajetta E (2000) Possible relationship of hemoglobin levels with survival in anemic cancer patients receiving chemotherapy. Proc Am Soc Clin Oncol 19: 605a (abstract 2381)
18. Macdougall IC, Gray S, Elston O, Breen C, Jenkins B, Browne J and Egrie J (1999) Pharmacokinetics of novel erythropoiesis stimulating protein compared with Epoetin alfa in dialysis patients. J Am Soc Nephrol 10: 2392-2395
19. Maraveya S and Pettengell R (1998) What is the role of erythropoietin in patients with solid tumors? Am Oncol 9: 239-241
20. Means RT Jr (1995) Pathogenesis of the anemia of chronic disease: a cytokine-mediated anemia. Stem Cells 13: 32-37
21. Miller CB, Jones RJ, Piantadosi S, Abeloff MD and Spivak JL (1990) Decreased erythropoietin response in patients with anemia of cancer. N Engl J Med 332: 1689-1692
22. Walker R (1987) Transfusion risks. Am J Clin Pathol 88: 371-378